

Richard Moriggl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7621245/publications.pdf>

Version: 2024-02-01

228
papers

13,278
citations

18436

62
h-index

29081

104
g-index

244
all docs

244
docs citations

244
times ranked

17071
citing authors

#	ARTICLE	IF	CITATIONS
1	Structural and utational nalysis of ember-specific STAT unctions. Biochimica Et Biophysica Acta - General Subjects, 2022, 1866, 130058.	1.1	3
2	Oncogenic TYK2^{P760L} kinase is effectively targeted by combinatorial TYK2, mTOR and CDK4/6 kinase blockade. Haematologica, 2022, , .	1.7	1
3	JAK–STAT core cancer pathway: An integrative cancer interactome analysis. Journal of Cellular and Molecular Medicine, 2022, 26, 2049-2062.	1.6	32
4	Thyroid and androgen receptor signaling are antagonized by Î¼–Crystallin in prostate cancer. International Journal of Cancer, 2021, 148, 731-747.	2.3	17
5	STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway. Oncogene, 2021, 40, 1091-1105.	2.6	42
6	TYK2 licenses non-canonical inflammasome activation during endotoxemia. Cell Death and Differentiation, 2021, 28, 748-763.	5.0	16
7	Opioids drive breast cancer metastasis through the Î²-opioid receptor and oncogenic STAT3. Neoplasia, 2021, 23, 270-279.	2.3	26
8	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	1.2	11
9	A centric view of JAK/STAT5 in intestinal homeostasis, infection, and inflammation. Cytokine, 2021, 139, 155392.	1.4	12
10	Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. Journal of Medicinal Chemistry, 2021, 64, 8486-8509.	2.9	28
11	STAT3 activation in large granular lymphocyte leukemia is associated with cytokine signaling and DNA hypermethylation. Leukemia, 2021, 35, 3430-3443.	3.3	20
12	Down-regulation of A20 promotes immune escape of lung adenocarcinomas. Science Translational Medicine, 2021, 13, .	5.8	10
13	A STAT5B–CD9 axis determines self-renewal in hematopoietic and leukemic stem cells. Blood, 2021, 138, 2347-2359.	0.6	23
14	Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers, 2021, 13, 3464.	1.7	5
15	A hydride transfer complex reprograms NAD metabolism and bypasses senescence. Molecular Cell, 2021, 81, 3848-3865.e19.	4.5	24
16	A Recurrent STAT5BN642H Driver Mutation in Feline Alimentary T Cell Lymphoma. Cancers, 2021, 13, 5238.	1.7	4
17	Proteomic Analysis Identifies NDUF51 and ATP5O as Novel Markers for Survival Outcome in Prostate Cancer. Cancers, 2021, 13, 6036.	1.7	7
18	Adipocyte STAT5 deficiency does not affect blood glucose homeostasis in obese mice. PLoS ONE, 2021, 16, e0260501.	1.1	2

#	ARTICLE	IF	CITATIONS
19	Proposed Diagnostic Criteria and Classification of Canine Mast Cell Neoplasms: A Consensus Proposal. <i>Frontiers in Veterinary Science</i> , 2021, 8, 755258.	0.9	16
20	The Diverse Roles of $\gamma\delta$ T Cells in Cancer: From Rapid Immunity to Aggressive Lymphoma. <i>Cancers</i> , 2021, 13, 6212.	1.7	13
21	Efficacy and Synergy of Small Molecule Inhibitors Targeting FLT3-ITD+ Acute Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 6181.	1.7	1
22	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	1.7	27
23	Cancer-associated fibroblast-derived WNT2 increases tumor angiogenesis in colon cancer. <i>Angiogenesis</i> , 2020, 23, 159-177.	3.7	174
24	Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. <i>Blood</i> , 2020, 136, 2786-2802.	0.6	17
25	Targeting STAT3 and STAT5 in Cancer. <i>Cancers</i> , 2020, 12, 2002.	1.7	7
26	STAT5 is required for lipid breakdown and beta-adrenergic responsiveness of brown adipose tissue. <i>Molecular Metabolism</i> , 2020, 40, 101026.	3.0	15
27	Advances in covalent kinase inhibitors. <i>Chemical Society Reviews</i> , 2020, 49, 2617-2687.	18.7	160
28	STAT5 is Expressed in CD34+/CD38 ^{low} Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	1.7	12
29	The neonatal microenvironment programs innate $\gamma\delta$ T cells through the transcription factor STAT5. <i>Journal of Clinical Investigation</i> , 2020, 130, 2496-2508.	3.9	18
30	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. <i>Blood</i> , 2020, 136, 387-400.	0.6	46
31	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	3.3	40
32	JAK-STAT inhibition impairs KRAS-driven lung adenocarcinoma progression. <i>International Journal of Cancer</i> , 2019, 145, 3376-3388.	2.3	54
33	STAT5a/b Deficiency Delays, but does not Prevent, Prolactin-Driven Prostate Tumorigenesis in Mice. <i>Cancers</i> , 2019, 11, 929.	1.7	12
34	Structural Implications of STAT3 and STAT5 SH2 Domain Mutations. <i>Cancers</i> , 2019, 11, 1757.	1.7	45
35	Structural and functional consequences of the STAT5BN642H driver mutation. <i>Nature Communications</i> , 2019, 10, 2517.	5.8	50
36	Cell Metabolism Control Through O-GlcNAcylation of STAT5: A Full or Empty Fuel Tank Makes a Big Difference for Cancer Cell Growth and Survival. <i>International Journal of Molecular Sciences</i> , 2019, 20, 1028.	1.8	12

#	ARTICLE	IF	CITATIONS
37	STAT5BN642H drives transformation of NKT cells: a novel mouse model for CD56+ T-LGL leukemia. <i>Leukemia</i> , 2019, 33, 2336-2340.	3.3	12
38	The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis. <i>Haematologica</i> , 2019, 104, 1907-1909.	1.7	13
39	Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. <i>Immunity</i> , 2019, 51, 1074-1087.e9.	6.6	72
40	Direct Targeting Options for STAT3 and STAT5 in Cancer. <i>Cancers</i> , 2019, 11, 1930.	1.7	65
41	Interplay of transcription factors STAT3, STAT1 and AP-1 mediates activity of the matrix metallo-proteinase-1 promoter in colorectal carcinoma cells. <i>Neoplasma</i> , 2019, 66, 357-366.	0.7	2
42	Editorial: Cytokines in liver diseases. <i>Cytokine</i> , 2019, 124, 154608.	1.4	1
43	Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression. <i>Cytokine</i> , 2019, 124, 154569.	1.4	47
44	High Keratin 8/18 Ratio Predicts Aggressive Hepatocellular Cancer Phenotype. <i>Translational Oncology</i> , 2019, 12, 256-268.	1.7	28
45	Pharmacologic IL-6R α inhibition in cholangiocarcinoma promotes cancer cell growth and survival. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2019, 1865, 308-321.	1.8	11
46	Crosstalk between inflammatory mediators and endoplasmic reticulum stress in liver diseases. <i>Cytokine</i> , 2019, 124, 154577.	1.4	54
47	The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease. <i>Cancer Cell</i> , 2019, 35, 125-139.e9.	7.7	43
48	STAT5 deficiency in hepatocytes reduces diethylnitrosamine-induced liver tumorigenesis in mice. <i>Cytokine</i> , 2019, 124, 154573.	1.4	14
49	STAT3 β is a tumor suppressor in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1989-2002.	2.5	20
50	Constitutive STAT5 activation regulates Paneth and Paneth-like cells to control <i>Clostridium difficile</i> colitis. <i>Life Science Alliance</i> , 2019, 2, e201900296.	1.3	20
51	Cover Image, Volume 16, Issue 1. <i>Veterinary and Comparative Oncology</i> , 2018, 16, i.	0.8	0
52	NGR (Asn-Gly-Arg)-targeted delivery of coagulase to tumor vasculature arrests cancer cell growth. <i>Oncogene</i> , 2018, 37, 3967-3980.	2.6	37
53	Tumor target amplification: Implications for nano drug delivery systems. <i>Journal of Controlled Release</i> , 2018, 275, 142-161.	4.8	99
54	Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. <i>Nature Communications</i> , 2018, 9, 697.	5.8	73

#	ARTICLE	IF	CITATIONS
55	Pharmacologic inhibition of STAT5 in acute myeloid leukemia. <i>Leukemia</i> , 2018, 32, 1135-1146.	3.3	112
56	<scp>AKT</scp>3 drives adenoid cystic carcinoma development in salivary glands. <i>Cancer Medicine</i> , 2018, 7, 445-453.	1.3	13
57	Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. <i>Leukemia</i> , 2018, 32, 1016-1022.	3.3	20
58	Implications of STAT3 and STAT5 signaling on gene regulation and chromatin remodeling in hematopoietic cancer. <i>Leukemia</i> , 2018, 32, 1713-1726.	3.3	166
59	The <scp>JAK2</scp>/<scp>STAT5</scp> signaling pathway as a potential therapeutic target in canine mastocytoma. <i>Veterinary and Comparative Oncology</i> , 2018, 16, 55-68.	0.8	19
60	Malignant Phenotypes in Metastatic Melanoma are Governed by SR-BI and its Association with Glycosylation and STAT5 Activation. <i>Molecular Cancer Research</i> , 2018, 16, 135-146.	1.5	21
61	Emerging therapeutic targets in myeloproliferative neoplasms and peripheral T-cell leukemia and lymphomas. <i>Expert Opinion on Therapeutic Targets</i> , 2018, 22, 45-57.	1.5	19
62	Life Under Hypoxia Lowers Blood Glucose Independently of Effects on Appetite and Body Weight in Mice. <i>Frontiers in Endocrinology</i> , 2018, 9, 490.	1.5	7
63	Normal and pathological erythropoiesis in adults: from gene regulation to targeted treatment concepts. <i>Haematologica</i> , 2018, 103, 1593-1603.	1.7	49
64	Synergistic cross-talk of hedgehog and interleukin-6 signaling drives growth of basal cell carcinoma. <i>International Journal of Cancer</i> , 2018, 143, 2943-2954.	2.3	23
65	A haunted beast: Targeting STAT5BN642H in T-Cell Neoplasia. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1435181.	0.3	3
66	Afatinib restrains K-RAS-driven lung tumorigenesis. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	99
67	P097 REGULATION OF PANETH CELL LINEAGES FOR REGIONAL IMMUNE SPECIALIZATION TO CONTROL COMORBIDITY OF C. DIFFICILE INFECTION WITH IBD. <i>Gastroenterology</i> , 2018, 154, S50.	0.6	0
68	STAT5 drives abnormal proliferation in autosomal dominant polycystic kidney disease. <i>Kidney International</i> , 2017, 91, 575-586.	2.6	41
69	O-GlcNAcylation of STAT5 controls tyrosine phosphorylation and oncogenic transcription in STAT5-dependent malignancies. <i>Leukemia</i> , 2017, 31, 2132-2142.	3.3	47
70	When the guardian sleeps: Reactivation of the p53 pathway in cancer. <i>Mutation Research - Reviews in Mutation Research</i> , 2017, 773, 1-13.	2.4	47
71	Autocrine WNT2 signaling in fibroblasts promotes colorectal cancer progression. <i>Oncogene</i> , 2017, 36, 5460-5472.	2.6	107
72	Combined targeting of STAT3 and STAT5: a novel approach to overcome drug resistance in chronic myeloid leukemia. <i>Haematologica</i> , 2017, 102, 1519-1529.	1.7	36

#	ARTICLE	IF	CITATIONS
73	A rare castration-resistant progenitor cell population is highly enriched in Pten null prostate tumours. <i>Journal of Pathology</i> , 2017, 243, 51-64.	2.1	27
74	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. <i>Blood</i> , 2017, 130, 2499-2503.	0.6	59
75	Human stem cells alter the invasive properties of somatic cells via paracrine activation of mTORC1. <i>Nature Communications</i> , 2017, 8, 595.	5.8	25
76	Expansion of <i>BCR<sup>+</sup>ABL<sup>1</sup></i> cells requires <i>PAK<sup>2</sup></i> but not <i>PAK<sup>1</sup></i> . <i>British Journal of Haematology</i> , 2017, 179, 229-241.	1.2	11
77	The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone. <i>Scientific Reports</i> , 2017, 7, 17498.	1.6	22
78	Adipocyte STAT5 deficiency promotes adiposity and impairs lipid mobilisation in mice. <i>Diabetologia</i> , 2017, 60, 296-305.	2.9	48
79	Adipocyte Glucocorticoid Receptor Deficiency Attenuates Aging- and HFD-Induced Obesity and Impairs the Feeding-Fasting Transition. <i>Diabetes</i> , 2017, 66, 272-286.	0.3	53
80	Steering of carcinoma progression by the YIN/YANG interaction of STAT1/STAT3. <i>BioScience Trends</i> , 2017, 11, 1-8.	1.1	27
81	STAT5BN642H is a driver mutation for T cell neoplasia. <i>Journal of Clinical Investigation</i> , 2017, 128, 387-401.	3.9	57
82	STAT5A/5B-specific expansion and transformation of hematopoietic stem cells. <i>Blood Cancer Journal</i> , 2017, 7, e514-e514.	2.8	6
83	Oncogenic STAT5 signaling promotes oxidative stress in chronic myeloid leukemia cells by repressing antioxidant defenses. <i>Oncotarget</i> , 2017, 8, 41876-41889.	0.8	33
84	Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model. <i>Oncotarget</i> , 2017, 8, 34141-34163.	0.8	72
85	Abstract 1184: Characterization of novel STAT5 inhibitors to interfere with the oncogenic activities of STAT5 in hematopoietic diseases. , 2017, , .		0
86	Abstract 4463: The coactivator oncogene AF1Q associates with STAT3 activation downstream of MET action in gastro-esophageal cancer patients. , 2017, , .		0
87	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. <i>Oncotarget</i> , 2016, 7, 8613-8624.	0.8	55
88	Hepatic Deletion of Janus Kinase 2 Counteracts Oxidative Stress in Mice. <i>Scientific Reports</i> , 2016, 6, 34719.	1.6	24
89	32 Cytokine-STAT5 Signaling Controls Intestinal Stem Cell Activation to Suppress Clostridium Difficile - Induced Gut Inflammation. <i>Gastroenterology</i> , 2016, 150, S11.	0.6	0
90	JAK-STAT signaling in cancer: From cytokines to non-coding genome. <i>Cytokine</i> , 2016, 87, 26-36.	1.4	186

#	ARTICLE	IF	CITATIONS
91	Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. <i>Experimental Dermatology</i> , 2016, 25, 305-310.	1.4	16
92	STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. <i>Cancer Discovery</i> , 2016, 6, 414-429.	7.7	124
93	NOX4-driven ROS formation mediates PTP inactivation and cell transformation in FLT3ITD-positive AML cells. <i>Leukemia</i> , 2016, 30, 473-483.	3.3	54
94	Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice. <i>Oncotarget</i> , 2016, 7, 12191-12205.	0.8	6
95	The ratio of STAT1 to STAT3 expression is a determinant of colorectal cancer growth. <i>Oncotarget</i> , 2016, 7, 51096-51106.	0.8	34
96	MLLT11/AF1q boosts oncogenic STAT3 activity through Src-PDGFR tyrosine kinase signaling. <i>Oncotarget</i> , 2016, 7, 43960-43973.	0.8	34
97	Natural compound methyl protodioscin protects against intestinal inflammation through modulation of intestinal immune responses. <i>Pharmacology Research and Perspectives</i> , 2015, 3, e00118.	1.1	33
98	ID: 263. <i>Cytokine</i> , 2015, 76, 112.	1.4	0
99	Stat5 gene dosage in T cells modulates CD8+T-cell homeostasis and attenuates contact hypersensitivity response in mice. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 67-79.	2.7	9
100	Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. <i>Nature Communications</i> , 2015, 6, 6285.	5.8	124
101	Lung Adenocarcinomas and Lung Cancer Cell Lines Show Association of MMP-1 Expression With STAT3 Activation. <i>Translational Oncology</i> , 2015, 8, 97-105.	1.7	31
102	ID: 66. <i>Cytokine</i> , 2015, 76, 77.	1.4	0
103	Persistent STAT5 activation in myeloid neoplasms recruits p53 into gene regulation. <i>Oncogene</i> , 2015, 34, 1323-1332.	2.6	34
104	Activated STAT5 Confers Resistance to Intestinal Injury by Increasing Intestinal Stem Cell Proliferation and Regeneration. <i>Stem Cell Reports</i> , 2015, 4, 209-225.	2.3	76
105	Stat5 Exerts Distinct, Vital Functions in the Cytoplasm and Nucleus of Bcr-Abl+ K562 and Jak2(V617F)+ HEL Leukemia Cells. <i>Cancers</i> , 2015, 7, 503-537.	1.7	17
106	STAT3 regulated ARF expression suppresses prostate cancer metastasis. <i>Nature Communications</i> , 2015, 6, 7736.	5.8	136
107	Oncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation. <i>Journal of Pathology</i> , 2015, 236, 445-456.	2.1	49
108	Epigenetic program and transcription factor circuitry of dendritic cell development. <i>Nucleic Acids Research</i> , 2015, 43, gkv1056.	6.5	62

#	ARTICLE	IF	CITATIONS
109	IGFBP7, a novel tumor stroma marker, with growth-promoting effects in colon cancer through a paracrine tumor-stroma interaction. <i>Oncogene</i> , 2015, 34, 815-825.	2.6	98
110	Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia. <i>Leukemia</i> , 2015, 29, 586-597.	3.3	111
111	AF1q is a novel TCF7 co-factor which activates CD44 and promotes breast cancer metastasis. <i>Oncotarget</i> , 2015, 6, 20697-20710.	0.8	35
112	YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model. <i>Oncotarget</i> , 2015, 6, 37678-37694.	0.8	24
113	Abstract 3284: Unfavorable outcomes of EWS-FLI1 expression in different tissues of a transgenic mouse model. , 2015, , .		0
114	Reliable Quantification of Protein Expression and Cellular Localization in Histological Sections. <i>PLoS ONE</i> , 2014, 9, e100822.	1.1	31
115	Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy. <i>Haematologica</i> , 2014, 99, 417-429.	1.7	50
116	A novel germline <i>JAK2</i> mutation in familial myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2014, 89, 117-118.	2.0	31
117	PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. <i>Leukemia</i> , 2014, 28, 629-641.	3.3	56
118	Editorial: Recovery from chemotherapy depends on STAT1 for replenishment of B lymphopoiesis. <i>Journal of Leukocyte Biology</i> , 2014, 95, 849-851.	1.5	2
119	SIAH2 antagonizes TYK2-STAT3 signaling in lung carcinoma cells. <i>Oncotarget</i> , 2014, 5, 3184-3196.	0.8	31
120	Inhibition of STAT5: A therapeutic option in BCR-ABL1-driven leukemia. <i>Oncotarget</i> , 2014, 5, 9564-9576.	0.8	39
121	Abstract 79: Deletion of STAT3 in a mouse model for metastatic melanoma. , 2014, , .		0
122	Abstract 61: A mouse model for small round cell tumors induced by the Ewing sarcoma oncogene EWS/FLI1. , 2014, , .		0
123	Abstract 108: Consequences of hepatic JAK2 deficiency for liver metabolism and hepatocarcinogenesis. , 2014, , .		0
124	Abstract 3138: IL-6/Stat3 signaling is an indispensable modulator of oncogene-induced cellular senescence. , 2014, , .		0
125	Src family kinases mediate cytoplasmic retention of activated STAT5 in BCR-ABL-positive cells. <i>Oncogene</i> , 2013, 32, 3587-3597.	2.6	30
126	A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis. <i>Cancer Cell</i> , 2013, 24, 167-181.	7.7	244

#	ARTICLE	IF	CITATIONS
127	STAT5 - a central player in BCR/ABL+ leukemia. <i>Experimental Hematology</i> , 2013, 41, S6.	0.2	0
128	Declined presentation. <i>Experimental Hematology</i> , 2013, 41, S48.	0.2	2
129	Ischemic brain injury: A consortium analysis of key factors involved in mesenchymal stem cell-mediated inflammatory reduction. <i>Archives of Biochemistry and Biophysics</i> , 2013, 534, 88-97.	1.4	60
130	Both STAT1 and STAT3 are favourable prognostic determinants in colorectal carcinoma. <i>British Journal of Cancer</i> , 2013, 109, 138-146.	2.9	92
131	TYK2â€“STAT1â€“BCL2 Pathway Dependence in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2013, 3, 564-577.	7.7	122
132	The Inhibition of Stat5 by a Peptide Aptamer Ligand Specific for the DNA Binding Domain Prevents Target Gene Transactivation and the Growth of Breast and Prostate Tumor Cells. <i>Pharmaceuticals</i> , 2013, 6, 960-987.	1.7	18
133	Reply. <i>Hepatology</i> , 2013, 58, 2210-2210.	3.6	0
134	BP5-087, a Novel STAT3 Inhibitor, Combines With BCR-ABL1 Inhibition To Overcome Kinase-Independent Resistance In Chronic Myeloid Leukemia. <i>Blood</i> , 2013, 122, 854-854.	0.6	0
135	The First European Interdisciplinary Ewing Sarcoma Research Summit. <i>Frontiers in Oncology</i> , 2012, 2, 54.	1.3	32
136	Acetylation and sumoylation control STAT5 activation antagonistically. <i>Jak-stat</i> , 2012, 1, 203-207.	2.2	12
137	PDGFR blockade is a rational and effective therapy for NPM-ALKâ€“driven lymphomas. <i>Nature Medicine</i> , 2012, 18, 1699-1704.	15.2	113
138	Hepatic growth hormone and glucocorticoid receptor signaling in body growth, steatosis and metabolic liver cancer development. <i>Molecular and Cellular Endocrinology</i> , 2012, 361, 1-11.	1.6	65
139	Stat5 as a Hematopoietic Master Regulator for Differentiation and Neoplasia Development. , 2012, , 153-167.		1
140	STAT5 triggers <i>BCR-ABL1</i> mutation by mediating ROS production in chronic myeloid leukaemia. <i>Oncotarget</i> , 2012, 3, 1669-1687.	0.8	64
141	Diverging fates of cells of origin in acute and chronic leukaemia. <i>EMBO Molecular Medicine</i> , 2012, 4, 283-297.	3.3	22
142	A mouse model to identify cooperating signaling pathways in cancer. <i>Nature Methods</i> , 2012, 9, 897-900.	9.0	15
143	Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinaseâ€“mediated loss of barrier function and inflammation. <i>EMBO Molecular Medicine</i> , 2012, 4, 109-124.	3.3	64
144	Growth-hormoneâ€“induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer. <i>Hepatology</i> , 2012, 55, 941-952.	3.6	42

#	ARTICLE	IF	CITATIONS
145	Abstract 4880: Disruption of STAT3 signaling promotes K-Ras induced lung tumorigenesis. , 2012, , .		0
146	TYK2-STAT1 Pathway Positively Regulates BCL2 Gene Expression in T-Cell Acute Lymphoblastic Leukemia. Blood, 2012, 120, 1470-1470.	0.6	1
147	STAT3 Inhibition Synergizes with BCR-ABL1 Inhibition to Overcome Kinase-Independent TKI Resistance in Chronic Myeloid Leukemia (CML). Blood, 2012, 120, 31-31.	0.6	2
148	7018 POSTER NFkB Activity Modulates the Oncogenic Potential of Stat3 in Prostate Cancer Development. European Journal of Cancer, 2011, 47, S490.	1.3	0
149	Serine phosphorylation of the Stat5a C-terminus is a driving force for transformation. Frontiers in Bioscience - Landmark, 2011, 16, 3043.	3.0	10
150	Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. Inflammatory Bowel Diseases, 2011, 17, S81.	0.9	0
151	High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood, 2011, 117, 3409-3420.	0.6	168
152	New perspectives in stem cell research: beyond embryonic stem cells. Cell Proliferation, 2011, 44, 9-14.	2.4	35
153	The role of Stat5 transcription factors as tumor suppressors or oncogenes. Biochimica Et Biophysica Acta: Reviews on Cancer, 2011, 1815, 104-114.	3.3	90
154	p19ARF/p14ARF controls oncogenic functions of signal transducer and activator of transcription 3 in hepatocellular carcinoma. Hepatology, 2011, 54, 164-172.	3.6	47
155	Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice. Hepatology, 2011, 54, 1398-1409.	3.6	100
156	Sensitized phenotypic screening identifies gene dosage sensitive region on chromosome 11 that predisposes to disease in mice. EMBO Molecular Medicine, 2011, 3, 50-66.	3.3	14
157	Variants in STAT5B Associate with Serum TC and LDL-C Levels. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1496-E1501.	1.8	5
158	STAT3 controls matrix metalloproteinase-1 expression in colon carcinoma cells by both direct and AP-1-mediated interaction with the MMP-1 promoter. Biological Chemistry, 2011, 392, 449-59.	1.2	37
159	Abstract 2809: Pathway dependence on the tyrosine kinase TYK2 in T-cell acute lymphoblastic leukemia. , 2011, , .		0
160	Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood, 2010, 116, 1548-1558.	0.6	56
161	Promising New Sources for Pluripotent Stem Cells. Stem Cell Reviews and Reports, 2010, 6, 15-26.	5.6	58
162	Stat5 is indispensable for the maintenance of <i>bcr/abl</i> -positive leukaemia. EMBO Molecular Medicine, 2010, 2, 98-110.	3.3	206

#	ARTICLE	IF	CITATIONS
163	Disruption of the growth hormone-Signal transducer and activator of transcription 5-Insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. <i>Hepatology</i> , 2010, 51, 1319-1326.	3.6	48
164	Effective targeting of STAT5-mediated survival in myeloproliferative neoplasms using ABT-737 combined with rapamycin. <i>Leukemia</i> , 2010, 24, 1397-1405.	3.3	26
165	Stat5 Promotes Survival of Mammary Epithelial Cells through Transcriptional Activation of a Distinct Promoter in <i>Akt1</i> . <i>Molecular and Cellular Biology</i> , 2010, 30, 2957-2970.	1.1	90
166	895 A PRO- AND ANTI-ONCOGENIC ROLE OF STAT3 IN HEPATOCELLULAR CARCINOMA PROGRESSION. <i>Journal of Hepatology</i> , 2010, 52, S348.	1.8	0
167	STAT5 requires the N-domain for suppression of miR15/16, induction of bcl-2, and survival signaling in myeloproliferative disease. <i>Blood</i> , 2010, 115, 1416-1424.	0.6	63
168	Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2010, 116, 3155-3155.	0.6	0
169	The dark and the bright side of Stat3: proto-oncogene and tumor-suppressor. <i>Frontiers in Bioscience - Landmark</i> , 2009, Volume, 2944.	3.0	44
170	Epidermal Growth Factor Receptor Signaling Synergizes with Hedgehog/GLI in Oncogenic Transformation via Activation of the MEK/ERK/JUN Pathway. <i>Cancer Research</i> , 2009, 69, 1284-1292.	0.4	189
171	Epidermal loss of JunB leads to a SLE phenotype due to hyper IL-6 signaling. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 20423-20428.	3.3	58
172	Correlation of malignancy parameters in colorectal carcinoma with up- and downstream signalling partners of STAT3. <i>Cell Communication and Signaling</i> , 2009, 7, .	2.7	0
173	Expression of Activated STAT5 in Neoplastic Mast Cells in Systemic Mastocytosis. <i>American Journal of Pathology</i> , 2009, 175, 2416-2429.	1.9	72
174	Unique Effects of KIT D816V in BaF3 Cells: Induction of Cluster Formation, Histamine Synthesis, and Early Mast Cell Differentiation Antigens. <i>Journal of Immunology</i> , 2008, 180, 5466-5476.	0.4	75
175	Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2. <i>Blood</i> , 2008, 111, 4511-4522.	0.6	101
176	Oncogenic Kit controls neoplastic mast cell growth through a Stat5/PI3-kinase signaling cascade. <i>Blood</i> , 2008, 112, 2463-2473.	0.6	97
177	Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. <i>Blood</i> , 2008, 112, 3878-3888.	0.6	87
178	The different functions of Stat5 and chromatin alteration through Stat5 proteins. <i>Frontiers in Bioscience - Landmark</i> , 2008, Volume, 6237.	3.0	39
179	A Detailed Protocol for Bacterial Artificial Chromosome Recombineering to Study Essential Genes in Stem Cells. <i>Methods in Molecular Biology</i> , 2008, 430, 269-293.	0.4	4
180	Direct glucocorticoid receptor-Stat5 interaction in hepatocytes controls body size and maturation-related gene expression. <i>Genes and Development</i> , 2007, 21, 1157-1162.	2.7	99

#	ARTICLE	IF	CITATIONS
181	Constitutive activation of Stat5 promotes its cytoplasmic localization and association with PI3-kinase in myeloid leukemias. <i>Blood</i> , 2007, 109, 1678-1686.	0.6	108
182	Nonredundant roles for Stat5a/b in directly regulating Foxp3. <i>Blood</i> , 2007, 109, 4368-4375.	0.6	488
183	Signal Transducer and Activator of Transcription 3 Activation Promotes Invasive Growth of Colon Carcinomas through Matrix Metalloproteinase Induction. <i>Neoplasia</i> , 2007, 9, 279-291.	2.3	117
184	STAT5 requires the N-domain to maintain hematopoietic stem cell repopulating function and appropriate lymphoid-myeloid lineage output. <i>Experimental Hematology</i> , 2007, 35, 1684-1694.	0.2	37
185	Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy. <i>Journal of Clinical Investigation</i> , 2007, 117, 1381-1390.	3.9	225
186	A role for STAT5A/B in protection of peripheral T-lymphocytes from postactivation apoptosis: Insights from gene expression profiling. <i>Cytokine</i> , 2006, 34, 143-154.	1.4	24
187	Clarifying the role of Stat5 in lymphoid development and Abelson-induced transformation. <i>Blood</i> , 2006, 107, 4898-4906.	0.6	192
188	Erythroid progenitor renewal versus differentiation: genetic evidence for cell autonomous, essential functions of EpoR, Stat5 and the GR. <i>Oncogene</i> , 2006, 25, 2890-2900.	2.6	56
189	STAT1 acts as a tumor promoter for leukemia development. <i>Cancer Cell</i> , 2006, 10, 77-87.	7.7	136
190	Autocrine PDGFR signaling promotes mammary cancer metastasis. <i>Journal of Clinical Investigation</i> , 2006, 116, 1561-1570.	3.9	307
191	Detection of Activated STAT5 in the Cytoplasm of Neoplastic Cells in Patients with AML, CML, and Systemic Mastocytosis.. <i>Blood</i> , 2006, 108, 2305-2305.	0.6	0
192	Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. <i>Blood</i> , 2005, 105, 3303-3311.	0.6	226
193	Stat5 tetramer formation is associated with leukemogenesis. <i>Cancer Cell</i> , 2005, 7, 87-99.	7.7	213
194	Persistent STAT3 Activation in Colon Cancer Is Associated with Enhanced Cell Proliferation and Tumor Growth. <i>Neoplasia</i> , 2005, 7, 545-555.	2.3	344
195	Glucocorticoid receptor function in hepatocytes is essential to promote postnatal body growth. <i>Genes and Development</i> , 2004, 18, 492-497.	2.7	110
196	Endogenous N-Terminal Truncated STAT5 Expressed from Alternative Start Codons Promotes SCF Signaling in Murine Primary Mast Cell Cultures.. <i>Blood</i> , 2004, 104, 815-815.	0.6	1
197	Jak1 deficiency leads to enhanced Abelson-induced B-cell tumor formation. <i>Blood</i> , 2003, 101, 4937-4943.	0.6	33
198	JunB inhibits proliferation and transformation in B-lymphoid cells. <i>Blood</i> , 2003, 102, 4159-4165.	0.6	76

#	ARTICLE	IF	CITATIONS
199	Reduced lymphomyeloid repopulating activity from adult bone marrow and fetal liver of mice lacking expression of STAT5. <i>Blood</i> , 2002, 99, 479-487.	0.6	134
200	Apoptosis Protection by the Epo Target Bcl-XL Allows Factor-Independent Differentiation of Primary Erythroblasts. <i>Current Biology</i> , 2002, 12, 1076-1085.	1.8	130
201	Gadd45 ³ Is Dispensable for Normal Mouse Development and T-Cell Proliferation. <i>Molecular and Cellular Biology</i> , 2001, 21, 3137-3143.	1.1	40
202	The antiapoptotic function of megakaryocyte growth and development factor (Peg-rmMGDF) is disrupted in STAT5ab ^{-/-} and JAK2 + ^{-/-} mice. <i>Experimental Hematology</i> , 2000, 28, 51.	0.2	2
203	A small amphipathic alpha-helical region is required for transcriptional activities and proteasome-dependent turnover of the tyrosine-phosphorylated Stat5. <i>EMBO Journal</i> , 2000, 19, 392-399.	3.5	114
204	Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5. <i>Blood</i> , 2000, 96, 2277-2283.	0.6	184
205	Regulation of the trans-activation potential of STAT5 through its DNA-binding activity and interactions with heterologous transcription factors. <i>Growth Hormone and IGF Research</i> , 2000, 10, S15-S20.	0.5	26
206	Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. <i>Genes and Development</i> , 2000, 14, 232-244.	2.7	152
207	Bone homeostasis in growth hormone receptor null mice is restored by IGF-I but independent of Stat5. <i>Journal of Clinical Investigation</i> , 2000, 106, 1095-1103.	3.9	225
208	Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of Stat5. <i>Blood</i> , 2000, 96, 2277-2283.	0.6	41
209	Antiapoptotic activity of Stat5 required during terminal stages of myeloid differentiation. <i>Genes and Development</i> , 2000, 14, 232-44.	2.7	147
210	Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl- and bcr/abl-induced transformation are independent of stat5. <i>Blood</i> , 2000, 96, 2277-83.	0.6	77
211	Induction of 3 ^β -Hydroxysteroid Dehydrogenase/5 ^α - ^β 4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13. <i>Molecular Endocrinology</i> , 1999, 13, 66-81.	3.7	67
212	Activation of STAT5 by IL-4 relies on Janus kinase function but not on receptor tyrosine phosphorylation, and can contribute to both cell proliferation and gene regulation. <i>International Immunology</i> , 1999, 11, 1283-1294.	1.8	39
213	Stat5 Is Required for IL-2-Induced Cell Cycle Progression of Peripheral T Cells. <i>Immunity</i> , 1999, 10, 249-259.	6.6	530
214	Stat5 Activation Is Uniquely Associated with Cytokine Signaling in Peripheral T Cells. <i>Immunity</i> , 1999, 11, 225-230.	6.6	161
215	Differential Roles of Cytokine Signaling during T-cell Development. <i>Cold Spring Harbor Symposia on Quantitative Biology</i> , 1999, 64, 389-396.	2.0	3
216	Induction of 3 ^β -Hydroxysteroid Dehydrogenase/5 ^α - ^β 4 Isomerase Type 1 Gene Transcription in Human Breast Cancer Cell Lines and in Normal Mammary Epithelial Cells by Interleukin-4 and Interleukin-13. <i>Molecular Endocrinology</i> , 1999, 13, 66-81.	3.7	47

#	ARTICLE	IF	CITATIONS
217	Presence or absence of TGF-beta determines IL-4-induced generation of type 1 or type 2 CD8 T cell subsets. <i>Journal of Immunology</i> , 1999, 162, 209-14.	0.4	26
218	Activation of STAT6 is not dependent on phosphotyrosine-mediated docking to the interleukin-4 receptor and can be blocked by dominant-negative mutants of both receptor subunits. <i>FEBS Journal</i> , 1998, 251, 25-35.	0.2	14
219	Dominant Negative Variants of the SHP-2 Tyrosine Phosphatase Inhibit Prolactin Activation of Jak2 (Janus Kinase 2) and Induction of Stat5 (Signal Transducer and Activator of Transcription 5)-Dependent Transcription. <i>Molecular Endocrinology</i> , 1998, 12, 556-567.	3.7	58
220	The Interleukin-4 Receptor Activates STAT5 by a Mechanism That Relies upon Common $\hat{\imath}^3$ -Chain. <i>Journal of Biological Chemistry</i> , 1998, 273, 31222-31229.	1.6	77
221	A Single Amino Acid in the DNA Binding Regions of STAT5A and STAT5B Confers Distinct DNA Binding Specificities. <i>Journal of Biological Chemistry</i> , 1998, 273, 33936-33941.	1.6	76
222	Activation of STAT proteins and cytokine genes in human Th1 and Th2 cells generated in the absence of IL-12 and IL-4. <i>Journal of Immunology</i> , 1998, 160, 3385-92.	0.4	21
223	Cytokine Receptor-independent, Constitutively Active Variants of STAT5. <i>Journal of Biological Chemistry</i> , 1997, 272, 30237-30243.	1.6	36
224	Comparison of the Transactivation Domains of Stat5 and Stat6 in Lymphoid Cells and Mammary Epithelial Cells. <i>Molecular and Cellular Biology</i> , 1997, 17, 3663-3678.	1.1	123
225	Specific DNA Binding of Stat5, but Not of Glucocorticoid Receptor, Is Required for Their Functional Cooperation in the Regulation of Gene Transcription. <i>Molecular and Cellular Biology</i> , 1997, 17, 6708-6716.	1.1	156
226	Deletion of the Carboxyl-Terminal Transactivation Domain of MGF-Stat5 Results in Sustained DNA Binding and a Dominant Negative Phenotype. <i>Molecular and Cellular Biology</i> , 1996, 16, 5691-5700.	1.1	262
227	Homodimerization of Interleukin-4 Receptor $\hat{\imath}^3$ Chain Can Induce Intracellular Signaling. <i>Journal of Biological Chemistry</i> , 1996, 271, 23634-23637.	1.6	67
228	Prolactin and interleukin-2 receptors in T lymphocytes signal through a MGF-STAT5-like transcription factor.. <i>Endocrinology</i> , 1995, 136, 5700-5708.	1.4	62